Astrazeneca (AZN) Gains from Investment Securities (2009 - 2026)

Astrazeneca (AZN) has reported Gains from Investment Securities for 18 consecutive years, with -$526.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 44.9% year-over-year to -$526.0 million; the TTM figure through Mar 2026 stood at -$176.0 million (down 379.37% YoY), while the FY2025 annual figure was -$13.0 million, down 225.0% from the prior year.
• Gains from Investment Securities came in at -$526.0 million for Q1 2026 at Astrazeneca, down from $2.2 billion in the prior quarter.
• The five-year high for Gains from Investment Securities was $2.2 billion in Q4 2025, with the low at -$1.2 billion in Q2 2025.
• Average Gains from Investment Securities over 5 years is -$96.4 million, with a median of -$526.0 million recorded in 2026.
• The largest YoY upside for Gains from Investment Securities was 795.37% in 2022 against a maximum downside of 214.2% in 2022.
• Year by year, Gains from Investment Securities stood at $1.8 billion in 2022, then plunged by 146.42% to -$836.0 million in 2023, then soared by 336.12% to $2.0 billion in 2024, then gained by 10.44% to $2.2 billion in 2025, then tumbled by 124.13% to -$526.0 million in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$526.0 million, $2.2 billion, and -$644.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.